Acticor Biotech Progresses Glenzocimab in Heart Attack Management
Acticor Biotech, a clinical-stage biopharmaceutical company, is making significant strides in addressing severe cardiovascular events with its investigational drug, glenzocimab. This innovative medication aims to tackle myocardial infarction, often referred to as a heart attack, which is a leading cause of mortality worldwide.
Gilles Avenard, the visionary Chief Executive Officer and founder of Acticor Biotech, sheds light on the harsh reality of myocardial infarction. "Each year, this condition contributes to nearly 9 million deaths, underlining the urgent need for better treatment approaches," he said. Avenard emphasizes the critical role of glenzocimab, especially in addressing microvascular thrombosis—a condition that complicates recovery from STEMI, a severe type of heart attack.
Currently, Acticor is engaged in a phase 2b clinical trial, known as LIBERATE, in collaboration with the University of Birmingham, UK. This pivotal study assesses the effectiveness of glenzocimab in reducing heart damage and preventing complications in patients experiencing ST-Elevation Myocardial Infarction (STEMI).
LIBERATE Study: Assessing Efficacy of Glenzocimab
The LIBERATE study, which aims to enroll over 212 candidates suffering from STEMI, is designed as a randomized, double-blind clinical trial. Participants will undergo percutaneous coronary interventions (PCI), with researchers carefully comparing the safety and effectiveness of glenzocimab administered in a dosage of 1000 mg against that of a placebo.
The study's primary outcome measures are to determine the decrease in myocardial infarction size by the 90-day mark following the event, a crucial indicator of long-term heart health. This research takes place at renowned clinical sites, including Queen Elizabeth Hospital and Northern General Hospital, both actively participating in patient recruitment since early 2024.
As of now, 27 individuals have joined the study, and the anticipated results are scheduled for release in the final quarter of 2026, potentially paving new paths for heart attack management.
GLORIA Study: Future Trials for Glenzocimab
In addition to LIBERATE, Acticor is preparing to kick off another phase 2 trial named GLORIA, which will further explore glenzocimab's role in myocardial infarction treatment. This study will target approximately 300 patients upon their emergency admission to cardiac intensive care units.
The main goal of the GLORIA trial is to monitor the efficacy of glenzocimab in reducing the extent of myocardial injury by Day 90 post-PCI, alongside evaluating safety throughout the treatment process. With this study, Acticor aims to test various dosages and optimize administration methods to facilitate timely intervention during emergencies.
Anticipated patient recruitment for GLORIA is slated to commence in early 2025, contingent upon Acticor's financial backing and continuation of the project following the necessary procedures.
About Acticor Biotech
Founded in 2013, Acticor Biotech is deeply committed to advancing treatments for cardiovascular emergencies and acute thrombotic diseases. The company is focused on glenzocimab, a cutting-edge humanized monoclonal antibody fragment designed to target the GPVI platelet receptor. This innovative approach seeks to enhance treatment options for conditions like acute ischemic stroke by avoiding the increased bleeding risk typically associated with existing therapies.
Through a series of international clinical studies involving over 600 stroke patients, Acticor has gleaned invaluable insights, which are now being applied to its trials concerning myocardial infarction. To date, glenzocimab has been administered to more than 800 subjects across various trials, with over 400 patients showing no notable safety concerns, solidifying its potential in emergency medicine.
The patents covering glenzocimab are robust, with protections extending until 2036 for the first family, securing Acticor's position in the market. The company is also pursuing the development of a biomarker specifically for stroke patients, underscoring its innovative spirit.
Supported by a diverse group of European and international investors, Acticor Biotech has been making waves in the biopharmaceutical landscape and has been publicly listed on Euronext Growth Paris since late 2021.
Frequently Asked Questions
What is glenzocimab?
Glenzocimab is an innovative drug developed by Acticor Biotech aimed at treating cardiovascular emergencies, particularly myocardial infarction.
What trials is Acticor currently conducting?
Acticor is currently conducting two trials—LIBERATE and GLORIA—to evaluate the efficacy and safety of glenzocimab in STEMI patients.
How does glenzocimab work?
Glenzocimab is a humanized monoclonal antibody fragment that targets the GPVI platelet receptor, reducing thrombosis in acute situations.
When can we expect the results from the LIBERATE study?
The results from the LIBERATE study are anticipated to be available in the final quarter of 2026.
How is Acticor Biotech supported?
Acticor Biotech is backed by a diverse array of European and international investors and has been publicly trading on Euronext Growth Paris since November 2021.
